Toxys Overview
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.2M
- Investors
-
10
Toxys General Information
Description
Developer of a vitro toxicity screening platform designed to identify hazardous and potential carcinogenic properties of novel compounds. The company's platform identifies genotoxic compounds, detects developmental toxicity, and provides a broad toxicity profile of compounds, enabling customers to make informed decisions on compound development pipeline and reduce animal testing.
Contact Information
Website
www.toxys.comCorporate Office
- De Limes 7
- 2342 DH Oegstgeest
- Netherlands
Corporate Office
- De Limes 7
- 2342 DH Oegstgeest
- Netherlands
Toxys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 12-Mar-2020 | $2.2M | Completed | Generating Revenue | ||
| 6. Grant | 22-Sep-2016 | Completed | Startup | |||
| 5. Early Stage VC (Series A) | 18-Feb-2016 | Completed | Startup | |||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup | |||
| 2. University Spin-Out | 01-Jan-2014 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2013 | Completed | Startup |
Toxys Comparisons
Industry
Financing
Details
Toxys Competitors (2)
One of Toxys’s 2 competitors is Vivaltes, a Corporation company based in Bunnik, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vivaltes | Corporation | Bunnik, Netherlands | ||||
| Resolian | Private Equity-Backed | Malvern, PA |
Toxys Patents
Toxys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3999660-A1 | Methods to determine the effect of an agent on mammalian embryonic development | Pending | 19-Jul-2019 | ||
| US-20220260552-A1 | Methods to determine the effect of an agent on mammalian embryonic development | Pending | 19-Jul-2019 | ||
| WO-2021015611-A1 | Methods to determine the effect of an agent on mammalian embryonic development. | Inactive | 19-Jul-2019 | G01N33/5023 |
Toxys Signals
Toxys Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Coöperatieve Rabobank | Investment Bank | Minority | ||
| KIKK Capital | Venture Capital | Minority | ||
| Libertatis Ergo Holding (LEH) | Venture Capital | Minority | ||
| EIT Health | Accelerator/Incubator | |||
| InnovationQuarter | Venture Capital | Minority |
Toxys FAQs
-
Where is Toxys headquartered?
Toxys is headquartered in Oegstgeest, Netherlands.
-
What is the size of Toxys?
Toxys has 34 total employees.
-
What industry is Toxys in?
Toxys’s primary industry is Biotechnology.
-
Is Toxys a private or public company?
Toxys is a Private company.
-
What is Toxys’s current revenue?
The current revenue for Toxys is .
-
How much funding has Toxys raised over time?
Toxys has raised $2.2M.
-
Who are Toxys’s investors?
Coöperatieve Rabobank, KIKK Capital, Libertatis Ergo Holding (LEH), EIT Health, and InnovationQuarter are 5 of 10 investors who have invested in Toxys.
-
Who are Toxys’s competitors?
Vivaltes and Resolian are competitors of Toxys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process